Contact our experts today
Composed of proven experts from the pharmaceutical industry, our team is ready to answer to your needs in any area of product development, commercialisation and early access programs, and life cycle management
“During the summer 2018, authorities become aware of the presence of some nitrosamines in API – (Valsartan – presence of N- nitrosodimethylamine (NDMA) – other sartans – presence of N-nitrosodiethylamine NDEA). These nitrosamines were already known as probable carcinogenic compounds but their presence in the sartans was not then identified.”
To read the whole document, please download the white paper.
Thank you for your interest in BlueReg.
The file will be sent to you by email.